

Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/G1B18BD9871BEN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: G1B18BD9871BEN

Abstracts

The 7 major Graves' disease markets are expected to exhibit a CAGR of 3.57% during 2024-2034.

The Graves' disease market has been comprehensively analyzed in IMARC's new report titled "Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Graves' disease is an autoimmune illness that affects the thyroid gland and causes an overproduction of thyroid hormones. This condition is more common in women and usually affects between the age of 20 to 50 years. Some of the prevalent symptoms of Graves' disease are rapid heartbeat, sweating, weight loss, nervousness, fatigue, irritability, etc. Additionally, a few patients may also develop an enlarged thyroid gland, red and swollen eyes, and experience changes in skin and hair. Graves' disease is typically diagnosed using a combination of physical examination, blood testing, and imaging investigations. A physical examination may indicate an enlarged thyroid gland as well as other hyperthyroidism symptoms, such as rapid heartbeat and excessive sweating. Blood tests are used to measure the levels of thyroid hormones and antibodies in the blood. Furthermore, numerous imaging tests, including ultrasound and radioactive iodine uptake, may be utilized to visualize the thyroid gland and determine the extent of the overproduction of hormones.

The growing prevalence of autoimmune disorders and the escalating need for efficient treatments with improved outcomes are primarily augmenting the global Graves' disease market. In addition to this, the widespread adoption of immunosuppressive therapy, such as glucocorticoids, to suppress the immune system and prevent it from attacking the thyroid gland is also acting as a significant growth-inducing factor. Moreover, the increasing utilization of beta-blockers to control the symptoms of Graves'

disease, including rapid heartbeat, tremors, anxiety, etc., by blocking the effects of thyroid hormones on the body is further creating a positive outlook for the market. Apart from this, several key players are making extensive investments in developing immunomodulatory drugs that target the underlying autoimmune process of Graves' disease. This, in turn, is also propelling the market growth. Additionally, the emerging popularity of radioactive iodine therapy among patients with severe symptoms or who cannot take anti-thyroid medications is further augmenting the market growth. Besides this, the growing preference for minimally invasive therapies, such as radiofrequency ablation and laser ablation, owing to their numerous advantages over traditional surgical treatments, including shorter recovery times, fewer complications, and lower risks of damage to surrounding tissues, is expected to drive the global Graves' disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Graves' disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Graves' disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Graves' disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Graves' disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Graves' disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Graves' disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Graves' disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Graves' disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Graves' disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Graves' disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of Graves' disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Graves' disease by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of Graves' disease by type across the seven major markets?

How many patients are diagnosed (2018-2034) with Graves' disease across the seven major markets?

What is the size of the Graves' disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Graves' disease?

What will be the growth rate of patients across the seven major markets?

Graves' Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Graves' disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Graves' disease market?

What are the key regulatory events related to the Graves' disease market?

What is the structure of clinical trial landscape by status related to the Graves' disease market?

What is the structure of clinical trial landscape by phase related to the Graves' disease market?

What is the structure of clinical trial landscape by route of administration related to the Graves' disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GRAVES' DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 GRAVES' DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 GRAVES' DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 GRAVES' DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 GRAVES' DISEASE - UNMET NEEDS

10 GRAVES' DISEASE - KEY ENDPOINTS OF TREATMENT

11 GRAVES' DISEASE - MARKETED PRODUCTS

- 11.1 List of Graves' Disease Marketed Drugs Across the Top 7 Markets

- 11.1.1 Propylthiouracil
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Tapazole (Methimazole)
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 GRAVES' DISEASE - PIPELINE DRUGS

- 12.1 List of Graves' Disease Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 ATX GD59 - Worg Pharmaceuticals
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Linsitinib - Sling Therapeutics
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
 - 12.1.3 Batoclimab - HanAll Biopharma/Harbour BioMed/Immunovant
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
 - 12.1.4 CFZ 533 - Novartis
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action

- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status
- 12.1.5 K1-70 - AV7 Limited
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. GRAVES' DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. GRAVES' DISEASE – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 GRAVES' DISEASE - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Graves' Disease - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Graves' Disease - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Graves' Disease - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Graves' Disease - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Graves' Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Graves' Disease - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Graves' Disease - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Graves' Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Graves' Disease - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Graves' Disease - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Graves' Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Graves' Disease - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Graves' Disease - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Graves' Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Graves' Disease - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Graves' Disease - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Graves' Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Graves' Disease - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Graves' Disease - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Graves' Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Graves' Disease - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Graves' Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Graves' Disease - Access and Reimbursement Overview

16 GRAVES' DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 GRAVES' DISEASE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 GRAVES' DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Graves' Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/G1B18BD9871BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1B18BD9871BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

